The new fast, effective and safe system for the biodecontamination of surfaces, guaranteed by pharmaceutical quality
In “Good Manufacturing Practice Considerations for Responding to COVID-19 Infection in Employees in Drug and Biological Products Manufacturing” – June 2020, FDA offers a guidance representing the current thinking of the Food and Drug Administration (FDA or Agency) on this topic.
The document focus on manufacturing controls to prevent contamination of drug, and, specifically suggests, to help prevent transmission among employees and contamination of drugs/materials by a COVID-19-infected employee engaged in drug manufacturing at the workplace, drug manufacturers should:
If a potential or actual viral contamination event is identified, drug manufacturers should promptly clean, disinfect, sanitize, and if necessary, sterilize affected equipment, surfaces, production areas, and facilities, before resuming manufacturing.
The Coronavirus emergency has imposed companies new rules and instructions to prevent any risk of contagion and to ensure employees work in a safe and protected environment.
In order to do this we reccomend programming interventions which aim at the complete disinfection of environments and surfaces, thus guaranteeing safety of working spaces.
+39 02 8728921